首页 | 官方网站   微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   150507篇
  免费   13863篇
  国内免费   9921篇
医药卫生   174291篇
  2024年   284篇
  2023年   1586篇
  2022年   3237篇
  2021年   6437篇
  2020年   4857篇
  2019年   4032篇
  2018年   4381篇
  2017年   4453篇
  2016年   4315篇
  2015年   6570篇
  2014年   8404篇
  2013年   8359篇
  2012年   12457篇
  2011年   13407篇
  2010年   9897篇
  2009年   8406篇
  2008年   9864篇
  2007年   9938篇
  2006年   9094篇
  2005年   8205篇
  2004年   6257篇
  2003年   6093篇
  2002年   5256篇
  2001年   3605篇
  2000年   2922篇
  1999年   2395篇
  1998年   1575篇
  1997年   1510篇
  1996年   1109篇
  1995年   1015篇
  1994年   863篇
  1993年   488篇
  1992年   540篇
  1991年   455篇
  1990年   389篇
  1989年   318篇
  1988年   287篇
  1987年   237篇
  1986年   213篇
  1985年   129篇
  1984年   121篇
  1983年   58篇
  1982年   44篇
  1981年   34篇
  1980年   35篇
  1979年   18篇
  1978年   21篇
  1975年   17篇
  1973年   16篇
  1972年   18篇
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
61.
Interleukin‐37 (IL‐37) is closely associated with several inflammatory diseases. However, the role of IL‐37 in the pathogenesis of rheumatoid arthritis (RA) remains unclear. The aim of this study was to assess the associations between serum levels of IL‐37 and disease activity, inflammatory cytokines, and bone loss in patients with RA. Serum cytokines levels were examined by Enzyme‐linked immunosorbent assay (ELISA). Radiographic bone erosion was assessed using the van der Heijde‐modified Sharp score and bone mineral density (BMD) was measured using DXA. Serum IL‐37 levels in RA patients were significantly higher than those in HCs (p < 0.001), and were significantly positively correlated with clinical parameters of disease activity and serum levels of IL‐17 and IL‐23. In addition, serum IL‐37 levels were significantly higher in patients with stage IV of radiographic bone erosion than those with stage III and stage I–II, and they were significantly higher in those with osteopenia and osteoporosis than in those with normal BMD. Our results suggest that serum IL‐37 levels were increased in patients with RA and were positively associated with disease activity, IL‐17/IL‐23 and bone loss in RA, suggesting that IL‐37 may play a critical role in the pathogenesis of RA.  相似文献   
62.
目的 探讨慕课在我国高等医学教育领域的应用现状和发展趋势,为本领域今后的研究提供参考。方法 检索中国知网、万方数据服务平台、维普数据库、中国生物医学文献数据库建库以来至2020年3月1日收录的相关文献,运用文献计量学方法对年发文量、期刊分布、基金支持、著者分布、被引频次、文献类型和高频关键词进行统计分析。将导出的资料用Excel 2010建立数据库,借助频数分析法进行描述性统计。结果 纳入文献754篇,分别收录于262种期刊;以医学教育类期刊为主;基金资助率达50%;黄坪、张欣、李鑫辉等7人为核心作者;以人体解剖学为代表的基础医学类课程应用研究最多;慕课应用研究以理论课程为主;课程评价包括终末性评价、形成性评价、平台考核、综合能力和自主学习能力5大方面;研究热点为基于慕课的混合式教学模式及其在护理教育、中医教育及继续医学教育中的应用。结论 近5年,慕课在我国高等医学教育中发展迅速,核心作者已形成,但缺乏深度合作。未来应增加实验(训)类课程的应用研究,同时应进一步完善实验性研究的设计及课程评价体系。  相似文献   
63.
64.
目的探讨低分子肝素钙预防腰椎退行性疾病术后深静脉血栓形成(DVT)的有效性和安全性。方法回顾性分析广安市广安区人民医院68例腰椎退行性疾病患者的临床资料,术后均采用抗凝预防血栓形成,按照术后预防DVT所采用方式的不同分为对照组和低分子肝素钙组。分析比较2组患者术后引流量、切口愈合情况、DVT发生率、皮下瘀斑情况、血小板数值、凝血功能、D-二聚体。结果术后2组患者引流量、切口愈合情况、皮下瘀斑情况、凝血功能相关指标比较,差异无统计学意义(P>0.05)。术前和术后1、10 d 2组患者血小板数量的变化差异无统计学意义(P>0.05)。DVT发生率2组患者比较差异有统计学意义(P<0.05)。术前及术后1 d 2组患者D-二聚体比较,差异无统计学意义(P>0.05);术后10 d,对照组患者D-二聚体显著增加,2组比较差异有统计学意义(P<0.05)。结论腰椎退行性疾病术后使用低分子肝素钙进行抗凝,可以显著降低DVT的发生率,具有良好的安全性。  相似文献   
65.
Apatinib, an oral small molecular receptor tyrosine kinase inhibitor (TKI) developed first in China, exerts antiangiogenic and antineoplastic function through selectively binding and inhibiting vascular endothelial growth factor receptor 2 (VEGFR-2). In this study, we aimed to explore the efficacy and safety profile of apatinib monotherapy, or combined with chemotherapy or endothelial growth factor receptor (EGFR)-TKI in heavily pretreated non-small cell lung cancer (NSCLC) patients with brain metastases. We performed a retrospective analysis for relapsed NSCLC patients with brain metastases from our institute, who received apatinib (250 mg or 500 mg p.o. qd) monotherapy, or combination with EGFR-TKI or chemotherapy as second or more line systemic therapy until disease progression or unacceptable toxicity occurred. The objective response rate (ORR), disease control rate (DCR), median progression-free survival (mPFS), median overall survival (mOS), and safety were analyzed. A total of 26 eligible patients were included: 24 patients diagnosed with adenocarcinoma, 2 with squamous carcinoma, and 14 patients harboring EGFR sensitizing mutations. The mPFS and mOS were 4.93 (range, 0.27−32.91; 95% CI 3.64−6.22) and 14.70 (range, 0.27−32.91; 95% CI 0.27−43.60) months for the whole group. The ORR and DCR were 7.7% (2/26) and 69.2% (18/26) for the entire lesions, and 7.7% (2/26) and 79.6% (20/26) for brain metastases, respectively. Compared with patients who received apatinib monotherapy, patients who received apatinib combination treatment had more favorable mPFS (11.77 vs. 2.27 months, p<0.05) and mOS (24.03 vs. 6.07 months, p<0.05). Treatment-related toxicities were tolerable including grade 1/2 hypertension, hand-and-foot syndrome, fatigue, nausea, liver dysfunction, myelosuppression, skin rash, and palpitation. In conclusion, apatinib exhibited high activity and good tolerance for NSCLC patients with brain metastasis, and it might become a potential choice for metastatic brain tumors in NSCLC patients.  相似文献   
66.
miRNA‐221 (miR‐221) is known to be abnormally expressed in many human cancers. The serum levels of miR‐221 have been reported as a tumor marker for malignant melanoma (MM). We hypothesized that the hair shaft miR‐221 levels may be increased in patients with MM. We therefore assessed the possibility that hair shaft miR‐221 levels could be a marker for MM. The hair shaft miR‐221 levels were significantly higher in patients with MM than controls. The rates of increased hair shaft miR‐221 levels above the cut‐off value were comparable to those of serum 5‐S‐CD, which is a tumor marker commonly used for MM. Measurements of the hair shaft miR‐221 levels could have potential clinical value in the detection of MM. This is the first report investigating the hair shaft levels of an miRNA in patients with MM. Our investigations offer new insight into the relationship between miR‐221 and MM, and may provide a new, non‐invasive way to screen for melanoma.  相似文献   
67.
目的 探讨一种快速简便鉴别羊水母血污染的方案。方法 选取30 例2019 年6~10 月羊水穿刺样本, 检测 羊水及母血DNA,将母血DNA 污染量换算对应体积全血量建立羊水母血DNA 污染梯度模型,运用尿干化学法及离 心沉渣镜检法检测母血污染情况。结果 羊水母血DNA 污染率为5%,10%,20% 和30%,尿干化学法检出率分别为 16.67%,60%,100% 和100%;离心沉渣镜检法检出率分别为60%,100%,100% 和100%。结论 尿干化学法及离心 沉渣镜检法联合检测可更简便快捷地进行羊水母血污染鉴定,检出率与母血DNA 污染率呈正比关系。  相似文献   
68.
ABSTRACT

Objectives: This paper is an examination of cancer/health communication factors (i.e. cancer/health information seeking, patient-provider communication (PPC), cancer screening information from providers) and screening for breast and cervical cancer among Asian Americans and five Asian ethnic groups (Chinese, Filipinos, Japanese, Koreans, Vietnamese) in comparison to Whites. Additionally, the relationship between cancer/health communication disparity and cancer screening gaps between Asian Americans and Whites was investigated.

Design: Data comes from a nationally representative sample of 2011–2014 Health Information National Trends Surveys (HINTS).

Results: Asian Americans and most Asian ethnic-groups reported significantly lower rates of cancer/health information seeking and lower evaluations for PPC as compared to Whites, though differences within Asian ethnic groups were observed (Koreans’ greater cancer/health information seeking, Japanese’ higher PPC evaluation). When the cancer/health communication factors were controlled, Asian Americans’ odds of cancer screening were increased. Especially, Asian Americans’ odds of adhering to the breast cancer screening guideline became nearly 1.4 times greater than Whites.

Conclusion: This research demonstrates that health organizations, providers, and Asian American patients’ collaborative efforts to increase the access to quality cancer information, to make culturally competent but straightforward screening recommendations, and to practice effective communication in medical encounters will contribute to diminishing cancer disparities among Asian Americans.  相似文献   
69.
70.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司    京ICP备09084417号-23

京公网安备 11010802026262号